体外膜氧合对磷化铝中毒合并心肌功能障碍患者结局的影响
该单中心回顾性研究纳入2011年1月至2016年6月共107例磷化铝中毒患者,其中67例按标准归为高危类别。比较接受ECMO(n=35)与仅接受常规治疗(n=32)患者的院内死亡率,ECMO组死亡率40%,常规治疗组84.4%(OR 0.47,95%CI 0.31-0.73)。存活者中ECMO组基线LVEF更低(中位24%,IQR 22-29 vs 中位32%,IQR 32-33.5,p<.003),出院时LVEF无显著差异(中位52%,IQR 48-60 vs 中位48%,IQR 47-49,p=.064)。逻辑回归显示较高SOFA评分、较低pH和未使用ECMO是死亡的独立预测因素。
要点
- 高危磷化铝中毒合并心肌功能障碍患者中,常规治疗加用VA-ECMO使院内死亡率从84.4%降至40%(OR 0.47,95%CI 0.31-0.73)。
- 存活者中ECMO组基线LVEF中位24%(IQR 22-29)低于常规组中位32%(IQR 32-33.5),出院时LVEF中位52%(IQR 48-60)与常规组中位48%(IQR 47-49)无显著差异(p=.064)。
- 逻辑回归分析显示较高SOFA评分、较低pH和未使用ECMO是死亡的独立预测因素。
- 研究为三级中心单中心回顾性研究,2011年1月至2016年6月共107例磷化铝中毒患者,67例归为高危类别。
适用人群与场景
- 三级中心收治的磷化铝中毒患者,2011年1月至2016年6月共107例,其中67例按标准归为高危类别。
- 高危患者中35例接受ECMO加常规治疗,32例仅接受常规治疗。
处置流程与药物剂量
- 高危磷化铝中毒患者中,在常规治疗基础上加用静脉-动脉体外膜氧合(VA-ECMO);原文未给出ECMO启动的具体阈值、流量或抗凝方案。
研究设计与关键结果
- 单中心回顾性研究,107例磷化铝中毒患者中67例为高危;ECMO组(n=35)院内死亡率40%,常规治疗组(n=32)84.4%,OR 0.47(95%CI 0.31-0.73)。
- 存活者中ECMO组基线LVEF中位24%(IQR 22-29)vs 常规组中位32%(IQR 32-33.5),p<.003;出院时ECMO组LVEF中位52%(IQR 48-60)vs 常规组中位48%(IQR 47-49),p=.064,无显著差异。
- 逻辑回归分析显示较高SOFA评分、较低pH和未使用ECMO是死亡的独立预测因素。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在高危磷化铝中毒患者中应用ECMO可使死亡率显著降低;较高基线SOFA评分是死亡的独立预测因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Aluminium phosphide (AlP) poisoning is associated with a high mortality rate when patients are complicated with myocardial dysfunction and refractory shock or severe metabolic acidosis. We studied the role of veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) in patients of AlP poisoning induced myocardial dysfunction. Methods and results: This is a tertiary care, single-centre, retrospective study. Between January 2011 and June 2016, total of 107 patients with AlP poisoning were identified and of those 67 were categorised in high-risk category as per the criteria. The in-hospital mortality of patients who received ECMO (n = 35) was compared to those who received conventional treatment (n = 32) only. The use of ECMO in addition to conventional treatment has reduced the in-hospital mortality from 84.4% to 40% (odds ratio: 0.47; 95% confidence interval 0.31-0.73). Among survivors, the ECMO group had a significantly lower baseline left ventricular ejection fraction (LVEF; median: 24%; IQR: 22-29 vs. median: 32%; IQR: 32-33.5; p < .003) but a non-significantly higher LVEF at the time of discharge (median: 52%; IQR: 48-60 vs. median: 48%; IQR: 47-49; p: .064) than did the conventional group. On logistic regression analysis the higher sequential organ failure assessment (SOFA) score, lower pH and the non-usage of ECMO were found to be the independent predictors of mortality. Conclusion: The use of ECMO in high-risk patient of AlP poisoning has resulted in a significant reduction in the mortality. A high baseline SOFA score has been found to be the independent predictor of mortality.
参考来源
- Mohan B, Gupta V, Ralhan S, et al. Impact of extra-corporeal membrane oxygenation on outcome of aluminium phosphide poisoning complicated with myocardial dysfunction. Clin Toxicol (Phila). 2019. PMID: 30856020. doi:10.1080/15563650.2019.1584297
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。